Regression of advanced melanoma upon withdrawal of immunosuppression: Case series and literature review

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1127-1132

  Dillon, P ^a   Thomas, N ^b   Sharpless, N ^a   Collichio, F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Immunosuppression; Melanoma; Myasthenia gravis; Transplant

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DRUG WITHDRAWAL; EARLY CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; MALE; MELANOMA; MYASTHENIA GRAVIS; NECK METASTASIS; PRIORITY JOURNAL; RISK FACTOR;

AGED; AZATHIOPRINE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MYASTHENIA GRAVIS; PROGNOSIS; REVIEW LITERATURE AS TOPIC; SKIN NEOPLASMS;

EID: 79951771271     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9348-z     Document Type: Article

References (66)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transpl Proc. 1969;1(1):106-12.
2. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006;154(3):472-7. (Pubitemid 43382655)
3. Sheil AG. Cancer after transplantation. World J Surg. 1986;10:389-96. (Pubitemid 16023916)
4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-13. (Pubitemid 38745589)
5. Arichi N, Kishikawa H, Nishimura K, et al. Malignancy following kidney transplantation. Transplant Proc. 2008;40(7):2400-2.
6. Randle HW. The historical link between solid-organ transplantation, immunosuppression, and skin cancer. Dermatol Surg. 2004;30:595-7. (Pubitemid 38525887)
7. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1-17.
8. Barker JN, MacDonald DM. Eruptive naevi following renal transplantation. Clin Exp Dermatol. 1988;13:123-5.
9. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal-transplant recipients. Lancet. 1981;1(8231):1196-9. (Pubitemid 11102743)
10. Sheil AG, Flavel S, Disney AP, et al. Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc. 1985;17:1685-8. (Pubitemid 15108276)
11. Dinh Q, Chong A. Melanoma in organ transplant recipients: the old enemy finds a new battleground. Aust J Dermatol. 2007;48:199-207. (Pubitemid 47621737)
12. Chapman J, Webster AC. Cancer report: ANZDATA Registry 2004 report, 2004:99.
13. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61(5):715-21. (Pubitemid 26097231)
14. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513-9.
15. Hasegawa W, Pond GR, Rifkind JT, et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005;35:51-5. (Pubitemid 40090056)
16. Lishner M, et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer. 1990;65(3):473-6.
17. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-904. (Pubitemid 27137189)
18. Socie G, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348-57. (Pubitemid 30056424)
19. Deeg HJ, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-92. (Pubitemid 26011854)
20. Ferry C, Gemayel G, Rocha V, et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant. 2007;40(3):219-24. (Pubitemid 47108464)
21. Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-83.
22. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87(9):3633-9. (Pubitemid 26129591)
23. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997;40:1580-6. (Pubitemid 27426150)
24. Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-43. (Pubitemid 39488667)
25. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-85. (Pubitemid 43736578)
26. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59(6):794-9. (Pubitemid 351847561)
27. Van den Borne BE, Landewe RB, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(11):1930-7. (Pubitemid 28506681)
28. Isomäki H, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31:691-6.
29. Wolfe F, Michaud K. The association of new cases of cancer with biologic therapy [abstract]. Arthritis Rheum. 2006; Suppl 54: S549.
30. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol. 2005;56(1):169-78. (Pubitemid 41278655)
31. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54(5):1608-18.
32. Kakrida M, Orengo I, Markus R. Sudden onset of multiple nevi after administration of 6-mercaptopurine in an adult with Crohn's disease: a case report. Int J Dermatol. 2005;44(4):334-6. (Pubitemid 40542154)
33. Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci. 2005;237(1-2): 39-43. (Pubitemid 41384012)
34. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-45. (Pubitemid 32259908)
35. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol. 2006;18:469-78. (Pubitemid 44199843)
36. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67. (Pubitemid 47017468)
37. Oble DA, Loewe R, Yu P, Mihm MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:3.
38. Hartmann A, Bedenk C, Keikavoussi P, Becker JC, Hamm H, Brocker EB. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges. 2008;6(12):1053-9.
39. Kalialis LV, Drzewiecki KT, Mohammadi M, Mehlsen AB, Klyver H. Spontaneous regression of metastases from malignant melanoma: a case report. Melanoma Res. 2008;18(4):279-83.
40. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer. 1960;13:79-81.
41. Stidolph NE. Malignant melanoma: regression of metastases after excision of primary growth. Proc R Soc Med. 1967;60(1):1.
42. Jensen OA, Andersen SR. Spontaneous regression of a malignant melanoma of the choroid. Acta Ophthalmol. 1974;52(2):173-82.
43. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Trial EST 1684. J Clin Oncol 1996;14(1):7-17. (Pubitemid 26019991)
44. Gogas H, Ioannovich IJ, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354(7):758-60.
45. Atkins MD, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
46. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4. (Pubitemid 35231542)
47. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698-703. (Pubitemid 351860862)
48. Riley LB, Agarwala SS. Melanoma vaccines. Expert Rev Vaccines. 2008;7(7):937-49.
49. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49(6):2518-25.
50. Hodi FS, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005;5:7.
51. Boratynska M, Watorek E, Smolska D, Patrzalek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transpl Proc. 2007;39(9):2736-9. (Pubitemid 350088107)
52. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. (Pubitemid 35363648)
53. Zattra E, Fortina AB, Bordignon M, Piaserico S, Alaibac M. Immunosuppression and melanocyte proliferation. Melanoma Res. 2009;19(2):63-8.
54. Boivin JF, O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. Cancer. 1988;61(12):2541-6.
55. Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Milan S, Omar RZ. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer. 1997;75(1):116-23. (Pubitemid 27007283)
56. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995;38(8):1120-7.
57. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997;44(16):1172-81. (Pubitemid 27326179)
58. Guenova E, Lichte V, Hoetzenecker W, et al. Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res. 2009;19(4):271-3.
59. Reutter JC, Long EM, Morrell DS, Thomas NE, Groben PA. Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol. 2007;24(2):135-7. (Pubitemid 46495913)
60. Potter T, Hardwick N, Mulherin D. Multiple malignant melanomas in a patient with RA treated with methotrexate. J Rheumatol. 1998;25(11):2282-3. (Pubitemid 28505884)
61. Jeannou J, Goupille P, Valat JP. Association of methotrexate, rheumatoid arthritis, and melanoma in 2 patients. J Rheumatol. 1997;24(7):1444-5. (Pubitemid 27353396)
62. Barnhill RL, Wiles JC. Malignant melanoma associated with multiple therapies for psoriasis. J Am Acad Dermatol. 1989;21(1):148-50. (Pubitemid 19171488)
63. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166-76. (Pubitemid 38155741)
64. Dreyer L, Mellemkjaer L, Hetland ML. Cancer in arthritis patients after anti-tumour necrosis factor therapy. Ugeskr Laeger. 2009;171(7):506-11.
65. Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol. 2009;34(4):524-6.
66. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 Suppl): S65-7. (Pubitemid 46552081)